157 related articles for article (PubMed ID: 22006869)
1. Immunosuppression with budesonide for liver transplant recipients with severe infections.
Bhat M; Ghali P; Wong P; Marcus V; Michel R; Cantarovich M; Metrakos P; Deschenes M
Liver Transpl; 2012 Feb; 18(2):262-3. PubMed ID: 22006869
[No Abstract] [Full Text] [Related]
2. Calcineurin inhibitors in liver transplantation: to be or not to be.
Castroagudín JF; Molina E; Varo E
Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
[TBL] [Abstract][Full Text] [Related]
3. Liver transplant: a primer.
Movahedi Z; Holt CD; Saab S
Exp Clin Transplant; 2010 Jun; 8(2):83-90. PubMed ID: 20565363
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab and liver transplantation: a review.
Dhesi S; Boland B; Colquhoun S
Curr Opin Organ Transplant; 2009 Jun; 14(3):245-9. PubMed ID: 19417659
[TBL] [Abstract][Full Text] [Related]
5. Role of budesonide in liver transplantation.
Åberg F
Transpl Immunol; 2014 May; 30(4):178-9. PubMed ID: 24727087
[No Abstract] [Full Text] [Related]
6. Steroid-free maintenance immunosuppression and ABO-incompatible transplantation.
Gloor J; Matas AJ
Transplantation; 2010 Mar; 89(6):648-9. PubMed ID: 20010327
[No Abstract] [Full Text] [Related]
7. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
9. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
[TBL] [Abstract][Full Text] [Related]
10. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
11. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
[TBL] [Abstract][Full Text] [Related]
12. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients.
Charlton M; Levitsky J; Aqel B; OʼGrady J; Hemibach J; Rinella M; Fung J; Ghabril M; Thomason R; Burra P; Little EC; Berenguer M; Shaked A; Trotter J; Roberts J; Rodriguez-Davalos M; Rela M; Pomfret E; Heyrend C; Gallegos-Orozco J; Saliba F
Transplantation; 2018 May; 102(5):727-743. PubMed ID: 29485508
[TBL] [Abstract][Full Text] [Related]
13. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
14. Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection.
Oettl T; Zuliani E; Gaspert A; Hopfer H; Dickenmann M; Fehr T
Transplantation; 2010 Mar; 89(6):702-6. PubMed ID: 20010328
[TBL] [Abstract][Full Text] [Related]
15. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes and quality of life after intestine transplantation.
Sudan D
Curr Opin Organ Transplant; 2010 Jun; 15(3):357-60. PubMed ID: 20445450
[TBL] [Abstract][Full Text] [Related]
17. Current immunosuppressive approaches in liver transplantation.
Iacob S; Cicinnati VR; Beckebaum S
Panminerva Med; 2009 Dec; 51(4):215-25. PubMed ID: 20195232
[TBL] [Abstract][Full Text] [Related]
18. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
19. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
[TBL] [Abstract][Full Text] [Related]
20. Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients.
Kerkar N; Morotti RA; Iyer K; Arnon R; Miloh T; Sturdevant M; Suchy F; Florman S; Emre S
Clin Transplant; 2011; 25(6):E584-91. PubMed ID: 21919961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
